416
Participants
Start Date
March 5, 2024
Primary Completion Date
June 30, 2027
Study Completion Date
February 28, 2028
CMV-MVA Triplex
The dosage used will be 5.0 x 10\^8 pfu, administered under sterile conditions intramuscularly. The CMV-MVA Triplex vaccine lots range in titre from 5.0 to 9.0 x 10\^8 pfu/mL in a supplied volume of 1.0 mL
Placebo for CMV-MVA Triplex
Arm 2 participants receive two doses of matching placebo CMV-MVA Triplex
WITHDRAWN
University of Alabama at Birmingham, School of Medicine, Birmingham
RECRUITING
University of California, San Diego School of Medicine, La Jolla
RECRUITING
University of Washington Medical Center: Transplantation, Seattle
RECRUITING
Stanford University, Redwood City
RECRUITING
University of California, San Francisco, San Francisco
RECRUITING
University of Miami, Jackson Memorial Hospital, Miami
RECRUITING
Emory University Hospital, Atlanta
RECRUITING
Northwestern University, Feinberg School of Medicine, Chicago
RECRUITING
Johns Hopkins University School of Medicine, Baltimore
RECRUITING
University of Michigan Medical Center, Ann Arbor
RECRUITING
Mayo Clinic, Rochester - College of Medicine and Science, Rochester
RECRUITING
University of Nebraska Medical Center, Omaha
RECRUITING
Duke University School of Medicine, Durham
RECRUITING
Oregon Health & Sciences University, Portland
RECRUITING
University of Pennsylvania School of Medicine, Philadelphia
RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
RECRUITING
Vanderbilt University School of Medicine, Nashville
RECRUITING
University of Texas Southwestern Medical Center, Dallas
National Institute of Allergy and Infectious Diseases (NIAID)
NIH